Vyvgart Hytrulo CIDP denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvgart hytrulo cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Issues "Not FDA-Approved" Denials for Vyvgart Hytrulo in CIDP — and Why That Is Incorrect

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc, subcutaneous formulation) has received FDA approval specifically for the treatment of CIDP in adults. A denial stating the drug is "not FDA-approved" is therefore factually incorrect for the CIDP indication and represents one of the most straightforward denial types to overturn on appeal. This type of denial often results from a coding mismatch, a formulary system that has not been updated to reflect the approval, or reviewer error.

## Why This Denial Is Immediately Appealable

Because the denial rests on an incorrect factual premise, the appeal can and should lead with documentary proof of the FDA approval. The FDA approval letter and the current prescribing label are publicly available and constitute conclusive evidence. BCBS plans are bound by their own coverage policies, which generally tie coverage to FDA approval for the approved indication — the very condition your prescriber is treating.

## Federal Appeal Framework

• Internal appeal: Under ACA §2719 and ERISA §503, submit a written internal appeal with the FDA approval documentation attached. Request a decision within the plan's regulatory deadline.
• External review: If the internal appeal is denied despite the evidence, escalate immediately to independent external review. Preserve this right by filing within the window shown on the denial notice (commonly around four months from the final internal denial).
• Expedited review: Request expedited processing if the patient's condition is deteriorating or if standard timelines would cause serious harm.
• State Insurance Commissioner: If the denial persists after a clear FDA approval, a complaint to your state's insurance regulator is warranted, as this may constitute a coverage violation.

## Documentation to Gather

1. FDA approval confirmation — the current FDA prescribing information (label) for Vyvgart Hytrulo, which states the approved indication. Available at the FDA's Drugs@FDA database. 2. Diagnosis documentation — neurology notes confirming the CIDP diagnosis, consistent with the FDA-approved indication. 3. Denial letter — preserve the exact denial language citing "not FDA-approved" so the appeal directly refutes it. 4. Prescriber letter — a brief letter from the neurologist confirming the drug is being used for its FDA-approved indication. 5. BCBS coverage policy — pull the current policy to identify any other criteria that may need to be addressed simultaneously to avoid a secondary denial.

## Criteria-Mapping Structure

Your appeal letter should include a dedicated section that quotes the denial's specific language and then immediately cites the FDA label page and indication statement that contradicts it. Then address any additional criteria in the BCBS medical policy to foreclose secondary denials. Obtain exact language from the FDA label and the insurer's current published policy — these are the authoritative sources.